Renal Denervation by Allegro System in Patients With Resistant Hypertension

Inclusion Criteria: * Age 18 - 65 years at time of randomization * Stable medication regimen including 3 or more antihypertensive medications of different classes, including a diuretic (with no changes for a minimum of 4 weeks prior to screening) and no expected changes for at least 6 months * 1\) Office SBP and/or DBP ≥160/100 mm Hg ( ≥ 150/95 mmHg for type II diabetic patients) , 2) ABPM 24 hour average SBP and/or DBP ≥140 and/or 90 mmHg * Main renal arteries with ≥4 mm diameter or with ≥20 mm treatable length (by visual estimation) * eGFR≥45 mL/min/1.73 m2 * Written informed consent Exclusion Criteria: * Type 1 diabetes mellitus * Secondary hypertension * Has an implantable cardioverter defibrillator (ICD) or pacemaker * Myocardial infarction, unstable angina pectoris, syncope, or a cerebrovascular accident within 6 months of the screening period * Intravascular thrombosis or unstable atherosclerotic plaques * Has hemodynamically significant valvular heart disease * Pregnant, nursing, or planning to be pregnant * Any serious medical condition that may adversely affect the safety of the participant or the study * Currently enrolled in another investigational drug or device trial Angiographic Exclusion Criteria: * Renal artery stenosis (≥50%) or renal artery aneurysm in either renal artery * History of prior renal artery intervention including balloon angioplasty or stenting * Multiple renal arteries where the main renal artery is estimated to supply \<75% of the kidney * Main renal arteries with \<4 mm diameter or with \<20 mm treatable length (by visual estimation) * Renal artery abnormalities